噻托溴铵联合沙美特罗替卡松治疗老年稳定期COPD的临床疗效及药物成本—效果分析  

Clinical effect and drug cost-effectiveness analysis of tiotropium bromide combined with salmeterol ficasone for elderly patients with stable COPD

作　　者：腊全琴 LA Quanqin(Aksu Second People′s Hospital,Akesu 843000,China)

机构地区：[1]新疆维吾尔自治区阿克苏地区第二人民医院,843000

出　　处：《临床合理用药杂志》2023年第6期22-25,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的 观察噻托溴铵联合沙美特罗替卡松治疗老年稳定期COPD的临床效及药物成本—效果。方法 选取2019年1月—2021年8月收治的老年稳定期COPD患者95例作为研究对象,采用随机数字表法分为A组47例和B组48例。随访6个月,A组、B组分别失访2例、3例,最终各纳入45例。A组患者采用沙美特罗替卡松治疗,B组患者在A组基础上增加噻托溴铵治疗。2组患者均随访6个月。比较2组治疗前及治疗7 d后炎性因子[肿瘤坏死因子-α(TNF-α)、白介素-8(IL-8)]、肺功能指标[用力肺活量(FVC)、深吸气量(IC)、第1秒用力呼气容积(FEV_(1))]、圣乔治呼吸问卷(SGRQ)评分,随访期COPD急性加重次数、成本(C)、效果(E)及成本—效果(C/E)。结果治疗7 d后,2组血清TNF-α、IL-8水平低于治疗前,FVC、IC、FEV_(1)高于治疗前,且B组血清TNF-α、IL-8水平低于A组,FVC、IC、FEV_(1)高于A组(P<0.05)。随访6个月,B组患者COPD急性加重次数少于A组(P<0.01)。治疗7 d后,2组SGRQ评分低于治疗前,且B组低于A组(P<0.01)。治疗后,B组C、C/E低于A组,E高于A组(P<0.01)。结论 噻托溴铵联合沙美特罗替卡松治疗老年稳定期COPD可更有效地减轻机体炎症,改善肺功能,减少COPD急性加重次数,同时可减少患者的治疗成本,提高生存质量。Objective To investigate the clinical effect and drug cost-effectiveness analysis of tiotropium bromide combined with salmeterol ficasone for elderly patients with stable COPD. Methods A total of 95 cases of elderly patients with stable COPD were selected from January 2019 to August 2021 in Aksu Second People′s Hospital, and they were divided into the group A(47 cases) and the group B(48 cases) according to the random number table method. After 6 months of follow-up, 2 cases in the group A and 3 cases in the group B were lost to follow-up, and finally 45 cases were included in each group. Patients in the group A were treated with salmeterol ficasone, and patients in the group B were given tiotropium bromide on the basis of group A. Both groups were followed-up for 6 months. Inflammatory factors(TNF-α, IL-8), pulmonary function indexes(FVC, IC, FEV_(1)), SGRQ score before and after 7 days of treatment, number of acute exacerbation of COPD, and C, E, C/E were compared between the two groups. Results After 7 days of treatment, serum levels of TNF-α, IL-8 in the two groups were lower than those before treatment, FVC, IC, FEV_(1)were higher than those before treatment, and serum levels of TNF-α, IL-8 of the group B were lower than those of the group A, FVC, IC, FEV_(1)were higher than those of the group A(P<0.05). Followed-up for 6 months, number of acute exacerbation of COPD of the group B was less than group A(P<0.01). After 7 days of treatment, SGRQ score in the two groups was lower than that before treatment, and that in the group B was lower than conyrol group(P<0.01). C, C/E of the group B were lower than those of the group A, and E was higher than that of the group A(P<0.01). Conclusion Tiotropium bromide combined with salmeterol ficasone can more effectively reduce inflammation for elderly patients with stable COPD, improve pulmonary function, reduce number of acute exacerbation of COPD and treatment costs, promote quality of life.

关 键 词：慢性阻塞性肺疾病 稳定期 老年人 噻托溴铵 沙美特罗替卡松 成本—效果分析 

分 类 号：R563.9[医药卫生—呼吸系统]